Across TCGA pan-cancer cohorts, ZFYVE21 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZFYVE21 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ZFYVE21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZFYVE21 expression acts as an unfavorable survival marker.
KIRP are the cancer types where ZFYVE21 Mutation most reproducibly stratifies survival.